EAST HANOVER, N.J., Oct. 16 Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in postmenopausal ...

Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts Tufts University Family Medicine Residency Program at Cambridge Health Alliance, Malden, Massachusetts An acute phase ...

Zoledronic acid 5 mg/100 mL bottle; solution for IV infusion. Paget’s disease of bone is characterized by greatly increased and disorderly bone remodeling. Excessive osteoclastic bone resorption is ...

EAST HANOVER, N.J., April 11 /PRNewswire/ -- New data show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass ...

EAST HANOVER, N.J., Aug. 17 -- Reclast(R) (zoledronic acid) Injection has been approved by the US Food and Drug Administration as the first and only once-yearly medicine for postmenopausal ...

Research published in the New England Journal of Medicine gives that an annual infusion of Novartis AG's Reclast after a mild hip fracture not only helps prevent another broken bone, it prolongs life ...

The FDA has approved Reclast (zoledronic acid, from Novartis) injection for the prevention of osteoporosis in women for two years with a single dose. This approval was based on a study involving more ...

The FDA has approved once-yearly Reclast (zoledronic acid, from Novartis) injection, a bisphosphonate, for the treatment and prevention of osteoporosis caused by glucocorticoids for patients expected ...